-
-
-
-
-
-
-
Xeris receives patent allowance for hypothyroidism drug candidate XP-8121
-
-
-
-
-
-
-
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Expects to Exceed Full-Year 2024 Financial Guidance
-
-
-
-
-
-
-
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
-
-
-
-
-
-
-
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
-
-
-
-
-
-
-
Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 2c, beats revenue
-
-
-
-
-
-
-
Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

